• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A system approach to pharmacodynamics. I: Theoretical framework.

作者信息

Veng-Pedersen P, Gillespie W R

机构信息

College of Pharmacy, University of Iowa, Iowa City 52242.

出版信息

J Pharm Sci. 1988 Jan;77(1):39-47. doi: 10.1002/jps.2600770108.

DOI:10.1002/jps.2600770108
PMID:3346822
Abstract

A general theoretical framework is constructed for the relationship between a pharmacokinetic response r (e.g., systemic drug concentration or input rate), and an observed pharmacologic effect response E. The overall relationship may be described mathematically by E = omega(r) = omega p(omega b(omega r(r))) where omega is an operator that describes the overall relationship, and omega r, omega b, and omega p are operators that describe the contributions of components of the pharmacodynamic system. The kinetic basis for applying certain general mathematical properties such as linearity are discussed. The result is the introduction of various specific mathematical structures that may be applied to pharmacodynamic systems [e.g., E = phi t(r), E = phi t(psi rr), E = phi p(psi pphi b(r)), and E = phi p(psi pphi b(psi rr))].

摘要

相似文献

1
A system approach to pharmacodynamics. I: Theoretical framework.
J Pharm Sci. 1988 Jan;77(1):39-47. doi: 10.1002/jps.2600770108.
2
New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.
J Pharmacokinet Biopharm. 1997 Jun;25(3):313-48. doi: 10.1023/a:1025723725312.
3
Generalized pharmacokinetic modeling for drugs with nonlinear binding: I. Theoretical framework.具有非线性结合的药物的广义药代动力学建模:I. 理论框架。
J Pharmacokinet Biopharm. 1993 Feb;21(1):99-124. doi: 10.1007/BF01061777.
4
A system approach to pharmacodynamics. II: Glyburide pharmacodynamics and estimation of optimal drug delivery.药效学的系统方法。II:格列本脲药效学及最佳药物递送的估计
J Pharm Sci. 1988 Jan;77(1):48-55. doi: 10.1002/jps.2600770109.
5
Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.药代动力学/药效学(PK/PD)建模的基本概念。
Int J Clin Pharmacol Ther. 1997 Oct;35(10):401-13.
6
Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.利用效应室浓度达峰时间结合药代动力学和药效学。
Anesthesiology. 2003 Aug;99(2):324-33. doi: 10.1097/00000542-200308000-00014.
7
Pharmacokinetic and pharmacodynamic modeling in vivo.体内药代动力学和药效学建模
Crit Rev Bioeng. 1981;5(4):273-322.
8
Pharmacodynamic system analysis of the biophase level predictor and the transduction function.
J Pharm Sci. 1992 Sep;81(9):925-34. doi: 10.1002/jps.2600810918.
9
Linear tripeptide conformation. Crystal structures of Cbz-glycylglycyltyrosine methyl ester and Cbz-glycyl(D,L)tyrosylglycine ethyl ester.
Int J Pept Protein Res. 1993 Feb;41(2):133-40.
10
Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.
Clin Pharmacol Ther. 1994 Sep;56(3):286-94. doi: 10.1038/clpt.1994.139.

引用本文的文献

1
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects.促红细胞生成素模拟抗体构建体CNTO 528在健康受试者中的药代动力学和药效学
Clin Pharmacokinet. 2009;48(9):601-13. doi: 10.2165/11317190-000000000-00000.
2
A 'bottom-up' approach for endo-PK/PD analysis.一种用于内镜药代动力学/药效学分析的“自下而上”方法。
Biopharm Drug Dispos. 2006 Oct;27(7):313-27. doi: 10.1002/bdd.508.
3
Bioavailability assessment from pharmacologic data: method and clinical evaluation.基于药理学数据的生物利用度评估:方法与临床评价。
J Pharmacokinet Biopharm. 1997 Jun;25(3):349-62. doi: 10.1023/a:1025775809382.
4
New mathematical implementation of generalized pharmacodynamic models: method and clinical evaluation.
J Pharmacokinet Biopharm. 1997 Jun;25(3):313-48. doi: 10.1023/a:1025723725312.
5
Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil.可变方向滞后最小化药效学方法的验证:阿芬太尼的心血管效应
Pharm Res. 1994 Jan;11(1):128-35. doi: 10.1023/a:1018966232183.
6
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? II. The response mapping operator (RMO) approach.药代动力学中的线性和非线性系统方法:它们能提供多少价值?II. 响应映射算子(RMO)方法。
J Pharmacokinet Biopharm. 1988 Oct;16(5):543-71. doi: 10.1007/BF01062384.
7
Linear and nonlinear system approaches in pharmacokinetics: how much do they have to offer? I. General considerations.
J Pharmacokinet Biopharm. 1988 Aug;16(4):413-72. doi: 10.1007/BF01062554.
8
Systems dynamics in clinical pharmacokinetics. An introduction.
Clin Pharmacokinet. 1989 Jul;17(1):27-44. doi: 10.2165/00003088-198917010-00003.
9
The use of kinetic-dynamic interactions in the evaluation of drugs.动力学-动态相互作用在药物评估中的应用。
Psychopharmacology (Berl). 1990;100(4):433-50. doi: 10.1007/BF02243994.
10
Noncompartmental versus compartmental modelling in clinical pharmacokinetics.临床药代动力学中的非房室模型与房室模型
Clin Pharmacokinet. 1991 Apr;20(4):253-62. doi: 10.2165/00003088-199120040-00001.